Develops antibody therapies and therapeutic vaccines aimed at misfolded proteins linked to neurodegenerative and other protein-misfolding diseases, and plans to license successful products to pharmaceutical partners.
10-K for FY2025, filed Mar 25, 2026
ProMIS plans to license products to pharmaceutical companies or form strategic alliances with them. Partners may fund development and, if a product reaches market, use their manufacturing and distribution networks.
10-K for FY2025, filed Mar 25, 2026
Parkinson’s disease
The older report described Parkinson’s disease as a possible additional area; the latest includes it among the diseases its antibody pipeline targets.
10-K for FY2022, filed Mar 8, 2023 10-K for FY2025, filed Mar 25, 20261 The Company may consider additional synucleinopathies, including Parkinson’s disease and Lewy Body dementia.View ↗
ProMIS has in-licensed a patented technology platform with the potential to deliver a portfolio of antibody therapies, therapeutic…View ↗
Competes with Alzheon, Alzinova, Chugai Pharmaceutical, Cognition Therapeutics, Eisai, Eli Lilly and, Grifols, KalGene Pharmaceuticals, Neurimmune, Novartis, Acumen Pharmaceuticals, Prothena Biosciences, Roche Holding, Wren Therapeutics, AbbVie, AC Immune, Alector, Anavex Life Sciences, Annovis Bio, and Athira Pharma
10-K for FY2025, filed Mar 25, 2026Other companies known to be developing therapies with Aβ/amyloid plaque-related targets include Alzheon, Inc., Alzinova AB, Chugai…View ↗
Loading...